Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

51.99 -0.60 (-1.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Thera

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. 
Via Benzinga
Recap: Viking Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
Earnings Preview: Viking Therapeutics
Via Benzinga
1 Under-the-Radar Stock That Could Triple By 2030
This small-cap biotech stock is going to compete against some giants. 
Via The Motley Fool
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
Via InvestorPlace
2 Rising Biotechs That Could Become the Next Novo Nordisk
Each of these companies has a big market in its sights. 
Via The Motley Fool
Earnings Scheduled For October 25, 2023
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is estimated to report quarterly earnings at $0.52 per share on revenue of $7.65 billion. 
Via Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune. 
Via InvestorPlace
2 Stocks That Could Soar This Year: Are They Buys?
They might perform well in 2024, but how will they do beyond that? 
Via The Motley Fool
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
The 3 Best Biotech Stocks to Buy in January 2024
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024. 
Via InvestorPlace
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
Why Viking Therapeutics Was Crushing It This Week
Nowadays, it's good to be a developer of next-generation weight loss drugs. 
Via The Motley Fool
What's Going On With Viking Therapeutics Shares Tuesday?
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b study 
Via Benzinga
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Why Are Stocks Down Today?
Stocks are down again on Wednesday as investors continue to feel the effects of several major catalysts hitting the market. 
Via InvestorPlace
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
Pfizer layoffs are a hot topic among PFE stock traders on Wednesday as they pour over the details of the job cuts amid a Covid slump. 
Via InvestorPlace
Topics Workforce
Exposures COVID-19 Layoff
Why Is Viking Therapeutics (VKTX) Stock Moving Today?
Viking Therapeutics stock is on the move Wednesday as investors react to results from the company's latest clinical trial! 
Via InvestorPlace
Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court... 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Jim Carmer Is 'A Seller' Of This Company Because 'Elon Musk Said That He Doesn't Like That Business'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Abbott Laboratories (NYSE: ABT) is a "very good company and will be up to the—let’s say—up to the challenge. I think that’s fair. 
Via Benzinga
Consolidation In Viking Therapeutics Provides An Opportunity
Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. 
Via Talk Markets
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
NASH treatments are projected to be one of the most sought-after indications in the coming years. 
Via The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.